Products
Faricimab Biosimilar Bispecific Antibody (VEGF-A × ANGPT2) for Research
Pre-Made Faricimab biosimilar, Bispecific mAb, Anti-VEGFA;ANGPT2 Antibody: Anti-VPF/VEGF/MVCD1;AGPT2/ANG2/LMPHM10 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Faricimab (INN) is a bispecific monoclonal antibody that is being investigated for diabetic macular edema.
Order Information
| Catalog No. | Package | Price(In USD) |
|---|---|---|
| GMP-Bios-ab-204-1mg | 1mg | |
| GMP-Bios-ab-204-10mg | 10mg | |
| GMP-Bios-ab-204-100mg | 100mg | |
| GMP-Bios-ab-204-xmg | ≥100mg |
Product Details
| Products Name (INN Index) | Pre-Made Faricimab biosimilar, Bispecific mAb, Anti-VEGFA;ANGPT2 Antibody: Anti-VPF/VEGF/MVCD1;AGPT2/ANG2/LMPHM10 therapeutic antibody |
| INN Name | Faricimab |
| Target | VEGFA;ANGPT2 |
| Format | Bispecific mAb |
| Derivation | Bispecific antibody |
| Species Reactivity | Human |
| CH1 Isotype | IgG1 |
| VD LC | Kappa;Lambda |
| Highest_Clin_Trial (Jan '20) | Preregistration |
| Est. Status | Active |
| 100% SI Structure | 1cz8:HL:YX;None |
| 99% SI Structure | None;None |
| 95-98% SI Structure | 1bj1:HL:KJ/6bft:AB:HL;4iml:AB:HL/4imk:AD:BC |
| Year Proposed | 2017 |
| Year Recommended | 2018 |
| Companies | Chugai Pharmaceutical;Roche |
| Conditions Approved | na |
| Conditions Active | Diabetic macular oedema;Wet age-related macular degeneration;Retinal oedema |
| Conditions Discontinued | na |
| Development Tech | Dual-Affinity Re-Targeting Technology |
About target - VEGFA
1. Protein Vascular endothelial growth factor A
2. Gene VEGFA
3. Organism Homo sapiens (Human)
Function
Growth factor active in angiogenesis, vasculogenesis and endothelial cell growth. Induces endothelial cell proliferation, promotes cell migration, inhibits apoptosis and induces permeabilization of blood vessels. Binds to the FLT1/VEGFR1 and KDR/VEGFR2 receptors, heparan sulfate and heparin. NRP1/Neuropilin-1 binds isoforms VEGF-165 and VEGF-145. Isoform VEGF165B binds to KDR but does not activate downstream signaling pathways, does not activate angiogenesis and inhibits tumor growth. Binding to NRP1 receptor initiates a signaling pathway needed for motor neuron axon guidance and cell body migration, including for the caudal migration of facial motor neurons from rhombomere 4 to rhombomere 6 during embryonic development (By similarity).
